Platelet-rich fibrin-released growth factor receptors (PRF-GFRs)

Platelet-rich fibrin (PRF)-released growth factor receptors represent a collective group of transmembrane proteins, primarily receptor tyrosine kinases and serine/threonine kinase receptors, that mediate the regenerative effects of PRF therapy (Miron et al., 2017). Upon activation of platelets and formation of a fibrin clot, a variety of signaling molecules including Platelet-Derived Growth Factor (PDGF), Vascular Endothelial Growth Factor (VEGF), and Transforming Growth Factor-beta (TGF-beta) are sequestered and gradually released from the fibrin matrix (Dohan Ehrenfest et al., 2009). These ligands bind to their respective receptors on mesenchymal stem cells, fibroblasts, and endothelial cells to stimulate essential processes such as angiogenesis, collagen synthesis, and cell proliferation (Ghanaati et al., 2014). This target complex is central to regenerative medicine, particularly in oral and maxillofacial surgery, orthopedics, and dermatology for enhancing wound healing and bone augmentation (Borie et al., 2015). While not targeted by a single small molecule, the therapeutic modulation of these receptors via autologous PRF provides a biocompatible approach to tissue engineering (Kobayashi et al., 2012). The efficacy of targeting these receptors depends heavily on the architecture of the fibrin matrix and the kinetics of ligand release.

Other names

Platelet-rich fibrin-released growth factor receptorsPRF-released ligand receptorsPlatelet-derived growth factor receptors (PDGFR)Vascular endothelial growth factor receptors (VEGFR)Transforming growth factor-beta receptors (TGFBR)Epidermal growth factor receptors (EGFR)

The mechanism involves the sustained release of endogenous growth factors (such as PDGF, VEGF, and TGF-beta) from the fibrin matrix of PRF, which then bind to and activate their specific high-affinity transmembrane receptors on target cells like fibroblasts, osteoblasts, and endothelial cells, initiating downstream signaling cascades (e.g., MAPK/ERK, PI3K/Akt, SMAD) for tissue repair (Miron et al., 2017; Dohan Ehrenfest et al., 2009).